Partnerships

Agreement seeks to advance novel drug targets and focus on therapies for ulcerative colitis.

The agreement is worth up to $552 million, depending on meeting set milestones.

-

An innovative approach to capacity management.

The PATH Malaria Vaccine Initiative and Inovio Pharmaceuticals have announced a follow-on collaboration to advance the development of malaria vaccines and new vaccine delivery technologies.

GlaxoSmithKline has formed a partnership with Vodafone to use mobile technology to help vaccinate more children against common infectious diseases in Africa.

Working together affords many unseen opportunities for pharmaceutical innovation.

Pfizer and Mylan have agreed to establish an exclusive long-term collaboration to develop, manufacture, distribute, and market generic drugs in Japan. The products included in the collaboration are expected to be sold under the Pfizer brand with joint labeling.

Gilead Sciences announced that it is entering into agreements with Indian generic drug manufacturers to enhance access in developing countries to its anti-HIV medicine, emtricitabine.

Collaborative R&D models coincide with new ways to fund translational research.

Future sponsor-contract provider relationships will require more integration.

The National Institute for Bioprocessing Research and Training (NIBRT) in Ireland and Waters are partnering on training and research to increase large-molecule characterization capacity and knowledge, according to an NIBRT press release.

The US Pharmacopeia (USP) continues to expand its collaboration with drug authorities around the world, this time with Brazil?s regulatory agency. USP and the Brazilian National Agency of Sanitary Surveillance (ANVISA) are teaming up to develop joint education activities for professionals involved in formulating and using pharmacopeial monograph standards in Brazil, according to news releases on the USP website.

Pfizer has partnered with the University of California?s San Diego Health Sciences (UCSD) in a drug-discovery collaboration that could see Pfizer invest up to $50 million over the next five years in the development of new therapies. The partnership will leverage UCSD?s expertise in neurosciences, cancer, inflammation, metabolism, clinical pharmacology, HIV, and pain.

In a speech at Carnegie Mellon University?s National Robotics Engineering Center last Friday, President Obama unveiled an Advanced Manufacturing Partnership (AMP) designed to reinvigorate the country?s manufacturing sector. The partnership between academics, business leaders, and science and technology agencies is intended to create jobs by helping US manufacturers reduce costs, improve quality, and accelerate product development.

Shanghai Pharmaceutical and Pfizer have signed a memorandum of understanding for the companies to jointly pursue potential business opportunities in China.

The authors present lessons learned from a case study of the transfer of a cell culture biotherapeutic process to a CMO.

Managing partnerships for the greater good.

ISCT Joins Forces with Roche and Genzyme to Launch Cell Therapy Industry Partnership

Shimadzu (Kyoto, Japan) and bioMérieux (Marcy l?Etoile, France) will commercialize a mass spectrometry system for bacterial identification in microbiology laboratories.

Thomson Reuters' Mark Gordon looks at how real partnership opportunities are developing in a virtual pharma world.

Waters Corporation (Milford, MA) and Ireland's National Institute for Bioprocessing Research and Training (NIBRT, Dublin, Ireland) have formed a collaboration that will create the world?s first database for glycan analysis by UltraPerformance liquid chromatography (UPLC).

This practicum combines business elements with scientific concepts.

Sanofi Pasteur, the vaccines division of the Sanofi-Aventis Group, has signed an agreement with KaloBios Pharmaceuticals for the development of humanized antibody fragment to both treat and prevent Pseudomonas aeruginosa infections.

ImmunoVaccine Technologies, Inc. (IVT) has formed a research agreement with Scancell, Ltd. to explore the potential of using IVT's DepoVax delivery system for Scancell's ImmunoBody DNA vaccines.